1Grundemann D, Gorboulev V, Gambaryan S, et al. Drug excretion mediated by a new prototype of polyspecific transporter[J]. Nature, 1994, 372(6506): 549-552.
2Jonker JW, Schinkel AH. Pharmacological and physiological functions of the polyspecific organic cation transporters: Octl, 2, and 3 (SLC22A1-3)[J]. J Pharmacol Exp Tiler, 2004, 308( 1 ) : 2-9.
3Jonker JW, Wagenaar E, Mol CA, et al. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Octl [Slc22al]) gene [J]. Mol Cell Biol, 2001, 21 (16): 5471-5477.
4Jonker JW, Wagenaar E, Van ES, et al. Deficiency in the organic cation transporters 1 and 2(Oct 1/Oct2 [S1c22a 1/Slc22 a2])in mice abolishes renal secretion of organic cations[J]. Mol Cell Biol, 2003, 23(21).. 7902-7908.
5Wang DS, Jonker JW, Kato Y, et al. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin[J]. J Pharmacol Exp Ther, 2002, 302(2): 510-515.
6Wang DS, Kusuhara H, Kato Y, et al. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin[J]. Mol Pharmacol, 2003, 63(4):844-848.
7Zwart R, Verhaagh S, Buitelaar M, et al. Impaired activity of the extraneuronal monoaminetransporter system known as uptake-2 in Orct3/Slc22a3-deficient mice[J]. Mol Cell Biol, 2001, 21(13): 4188-4196.
8Saborowski M, Kullak-Ublick GA, Eloranta JJ. The human organic cation transporter-I gene is transactivated by hepatocyte nuclear factor-4alpha [J]. J. Pharmacol Exp Ther, 2006, 317(2): 778-785.
9Maeda T, Yotsumoto T, Oyabu M, et al. Effect of glucocorticoid receptor ligand dexamethasone on the expression of organic cation transporter in rat liver[J]. Drug Metab Pharmacokinet, 2008, 23(1): 67-72.
10Shu Y, Bello CL, Mangravite LM, et al. Functional characteristics and steroid hormonemediated regulation of an organic cation transporter in bladin-Darby canine kidney cells[J]. J Pharmacol Exp Tiler. 2001, 299 (1): 392-398.
3De Groot M J, Ekins S. Pharmacophore modeling of cytochromes p450[J]. Adv Drug Deliv Rev, 2002, 54(3) : 367.
4Ghanayem B I, Hoffler U: Investigation of xenobioties metabolism, genotoxicity, and carcinogenicity using Cyp2e1 (-/-) mice [ J]. Curr Drug Metab,2007, 8(7) : 728.
5Alvarez-Gonzalez I, Madrigal-Bujaidar E, Dorado V, et al. Inhibitory effect of naringin on the micmnuelei induced by ifosfamide in mouse, and evaluation of its modulatory effect on the Cyp3a subfamily[J]. Murat Res, 2001, 480-481 (1) : 171.
6Kim H J, Chang E J, Cho S H, et al. Antioxidative activity of resveratrol and its derivatives isolated from seeds of Paeonia lactiflora[ J ]. Biosci Biotechnol Biochem, 2002, 66 (9) : 1990.
7Fagerholm U, Johansson M, Lennernas H. Comparison between permeability coefficients in rat and human jejunum [ J ]. Pharm Res, 1996, 13: 1336-1342.
8Zuo Zhong, Zhang Li, Zhou Limin, et al. Intestinal absorption of hawthorn flavonoids-in vitro, in situ and in vivo correlations[ J]. Life Sciences, 2006, 79: 2455-2462.
9Schurgers N, Bijdendijk J, Tukker J J, et al. Comparison of four experimental techniques for studying drug absorption kinetics in the anesthetized rat in situ[ J]. Jpharm Sci, 1986: 75(2) : 117- 119.
